Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Apr;35(4):750–752. doi: 10.1128/aac.35.4.750

Loracarbef versus cefaclor in the treatment of urinary tract infections in women.

A Iravani 1
PMCID: PMC245091  PMID: 2069382

Abstract

In a double-blind, prospective, randomized study, 108 college women with acute urinary tract infections were treated for 7 days with either loracarbef (LY163892) at 200 mg once daily (n = 53) or cefaclor at 250 mg three times daily (n = 55). The cure rates at 5 to 9 days after treatment in the loracarbef and cefaclor groups were 96 and 90%, respectively. Both loracarbef and cefaclor are safe, well tolerated, and effective in the treatment of urinary tract infections in women.

Full text

PDF
750

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauer A. W., Kirby W. M., Sherris J. C., Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966 Apr;45(4):493–496. [PubMed] [Google Scholar]
  2. Bill N. J., Washington J. A., 2nd Comparison of in vitro activity of cephalexin, cephradine, and cefaclor. Antimicrob Agents Chemother. 1977 Mar;11(3):470–474. doi: 10.1128/aac.11.3.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. CUTLER S. J., EDERER F. Maximum utilization of the life table method in analyzing survival. J Chronic Dis. 1958 Dec;8(6):699–712. doi: 10.1016/0021-9681(58)90126-7. [DOI] [PubMed] [Google Scholar]
  4. Cao C., Chin N. X., Neu H. C. In-vitro activity and beta-lactamase stability of LY163892. J Antimicrob Chemother. 1988 Aug;22(2):155–165. doi: 10.1093/jac/22.2.155. [DOI] [PubMed] [Google Scholar]
  5. Gurwith M. J., Stein G. E., Gurwith D. Prospective comparison of amoxicillin-clavulanic acid and cefaclor in treatment of uncomplicated urinary tract infections. Antimicrob Agents Chemother. 1983 Nov;24(5):716–719. doi: 10.1128/aac.24.5.716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Howard A. J., Dunkin K. T. Comparative in-vitro activity of a new oral carbacephem, LY163892. J Antimicrob Chemother. 1988 Oct;22(4):445–456. doi: 10.1093/jac/22.4.445. [DOI] [PubMed] [Google Scholar]
  7. Iravani A., Pryor N., Richard G. A. Treatment of acute uncomplicated urinary tract infections by cephalexin, with special reference to the antibody-coated bacteria. Int J Clin Pharmacol Ther Toxicol. 1982 Mar;20(3):97–100. [PubMed] [Google Scholar]
  8. Iravani A., Richard G. A. Amoxicillin-clavulanic acid versus cefaclor in the treatment of urinary tract infections and their effects on the urogenital and rectal flora. Antimicrob Agents Chemother. 1986 Jan;29(1):107–111. doi: 10.1128/aac.29.1.107. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Iravani A., Richard G. A., Baer H. Treatment of uncomplicated urinary tract infections with trimethoprim versus sulfisoxazole, with special reference to antibody-coated bacteria and fecal flora. Antimicrob Agents Chemother. 1981 May;19(5):842–850. doi: 10.1128/aac.19.5.842. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Iravani A., Richard G. A., Johnson D., Bryant A. A double-blind, multicenter, comparative study of the safety and efficacy of cefixime versus amoxicillin in the treatment of acute urinary tract infections in adult patients. Am J Med. 1988 Sep 16;85(3A):17–23. doi: 10.1016/0002-9343(88)90459-7. [DOI] [PubMed] [Google Scholar]
  11. Iravani A., Richard G. A. Single-dose cefuroxime axetil versus multiple-dose cefaclor in the treatment of acute urinary tract infections. Antimicrob Agents Chemother. 1989 Aug;33(8):1212–1216. doi: 10.1128/aac.33.8.1212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Iravani A., Richard G. A. Treatment of urinary tract infections with a combination of amoxicillin and clavulanic acid. Antimicrob Agents Chemother. 1982 Oct;22(4):672–677. doi: 10.1128/aac.22.4.672. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jones R. N., Barry A. L. Antimicrobial activity of LY163892, an orally administered 1-carbacephem. J Antimicrob Chemother. 1988 Sep;22(3):315–320. doi: 10.1093/jac/22.3.315. [DOI] [PubMed] [Google Scholar]
  14. Jordan P. A., Iravani A., Richard G. A., Baer H. Urinary tract infection caused by Staphylococcus saprophyticus. J Infect Dis. 1980 Oct;142(4):510–515. doi: 10.1093/infdis/142.4.510. [DOI] [PubMed] [Google Scholar]
  15. Knapp C. C., Washington J. A., 2nd In vitro activities of LY163892, cefaclor, and cefuroxime. Antimicrob Agents Chemother. 1988 Jan;32(1):131–133. doi: 10.1128/aac.32.1.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Nelson J. D., Shelton S., Kusmiesz H. Pharmacokinetics of LY163892 in infants and children. Antimicrob Agents Chemother. 1988 Nov;32(11):1738–1739. doi: 10.1128/aac.32.11.1738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Orskov I., Orskov F., Jann B., Jann K. Serology, chemistry, and genetics of O and K antigens of Escherichia coli. Bacteriol Rev. 1977 Sep;41(3):667–710. doi: 10.1128/br.41.3.667-710.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Rotschafer J., Crossley K., Zaske D., Viste R. Comparative study of cefaclor and amoxicillin in treatment of urinary tract infection. Urology. 1979 Sep;14(3):233–236. doi: 10.1016/0090-4295(79)90489-8. [DOI] [PubMed] [Google Scholar]
  19. Rous S. N. A comparison of cefaclor versus trimethoprim-sulfamethoxazole combination in the treatment of acute urinary infections. J Urol. 1981 Feb;125(2):228–229. doi: 10.1016/s0022-5347(17)54981-2. [DOI] [PubMed] [Google Scholar]
  20. Smith P. B., Tomfohrde K. M., Rhoden D. L., Balows A. API system: a multitube micromethod for identification of Enterobacteriaceae. Appl Microbiol. 1972 Sep;24(3):449–452. doi: 10.1128/am.24.3.449-452.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Williams K. J., Hebblethwaite E. M., Brown G. W., Cox D. M., Plested S. J. Cefuroxime axetil in the treatment of uncomplicated UTI: a comparison with cefaclor and augmentin. Drugs Exp Clin Res. 1987;13(2):95–99. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES